Bionano Historical Income Statement
| BNGO Stock | USD 0.28 0.01 3.45% |
Historical analysis of Bionano Genomics income statement accounts such as Interest Income of 3.5 M, Depreciation And Amortization of 14.4 M or Interest Expense of 5.4 M can show how well Bionano Genomics performed in making a profits. Evaluating Bionano Genomics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Bionano Genomics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Bionano Genomics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bionano Genomics is a good buy for the upcoming year.
Bionano |
About Bionano Income Statement Analysis
Bionano Genomics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Bionano Genomics shareholders. The income statement also shows Bionano investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Bionano Genomics Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Bionano Genomics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Bionano Genomics minus its cost of goods sold. It is profit before Bionano Genomics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bionano Genomics. It is also known as Bionano Genomics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Bionano Genomics income statement and represents the costs associated with goods and services Bionano Genomics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Bionano Genomics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Bionano Genomics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.At this time, Bionano Genomics' Other Operating Expenses is very stable compared to the past year. As of the 12th of November 2024, Research Development is likely to grow to about 56.7 M, while Net Interest Income is likely to drop (1.9 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 927K | 298K | 5.1M | 5.4M | Depreciation And Amortization | 4.0M | 10.1M | 13.7M | 14.4M |
Bionano Genomics income statement Correlations
Click cells to compare fundamentals
Bionano Genomics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bionano Genomics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Tax Provision | 21.0K | 29.2K | (5.7M) | 1.9M | 62K | 65.1K | |
| Net Interest Income | (2.3M) | (2.5M) | (691K) | 1.2M | (1.8M) | (1.9M) | |
| Interest Income | 2.3M | 0.0 | 236K | 1.5M | 3.3M | 3.5M | |
| Depreciation And Amortization | 1.1M | 1.5M | 4.0M | 10.1M | 13.7M | 14.4M | |
| Interest Expense | 2.3M | 2.5M | 927K | 298K | 5.1M | 5.4M | |
| Selling General Administrative | 20.2M | 31.1M | 58.5M | 88.6M | 93.5M | 98.2M | |
| Total Revenue | 10.1M | 8.5M | 18.0M | 27.8M | 36.1M | 37.9M | |
| Gross Profit | 3.4M | 2.8M | 3.9M | 5.9M | 9.6M | 4.9M | |
| Other Operating Expenses | 36.0M | 47.1M | 95.1M | 159.5M | 175.5M | 184.3M | |
| Operating Income | (25.9M) | (38.6M) | (77.1M) | (131.7M) | (139.4M) | (132.5M) | |
| Net Income From Continuing Ops | (29.8M) | (41.1M) | (72.4M) | (132.6M) | (232.5M) | (220.9M) | |
| Ebit | (25.9M) | (38.6M) | (80.9M) | (140.5M) | (139.4M) | (132.5M) | |
| Research Development | 9.1M | 10.3M | 22.5M | 49.0M | 54.0M | 56.7M | |
| Ebitda | (24.7M) | (37.1M) | (76.9M) | (130.4M) | (125.7M) | (119.4M) | |
| Cost Of Revenue | 6.8M | 5.7M | 14.1M | 21.9M | 26.6M | 27.9M | |
| Total Operating Expenses | 29.2M | 41.3M | 81.0M | 137.6M | 149.0M | 156.4M | |
| Income Before Tax | (29.8M) | (41.1M) | (78.2M) | (130.7M) | (232.4M) | (220.8M) | |
| Total Other Income Expense Net | (3.9M) | (2.6M) | (1.1M) | 986K | (93.0M) | (88.4M) | |
| Net Income Applicable To Common Shares | (29.8M) | (41.1M) | (72.4M) | (132.6M) | (119.3M) | (113.4M) | |
| Net Income | (29.8M) | (41.1M) | (72.4M) | (132.6M) | (232.5M) | (220.9M) | |
| Income Tax Expense | 21.0K | 29.2K | (5.7M) | 1.9M | 62K | 65.1K | |
| Reconciled Depreciation | 1.1M | 1.5M | 3.4M | 9.8M | 13.9M | 14.6M | |
| Non Operating Income Net Other | (1.6M) | (6.9K) | (360K) | (223K) | (200.7K) | (190.7K) |
Pair Trading with Bionano Genomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bionano Stock
Moving against Bionano Stock
| 0.84 | DRUG | Bright Minds Biosciences Downward Rally | PairCorr |
| 0.57 | VCYT | Veracyte | PairCorr |
| 0.55 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.55 | VERA | Vera Therapeutics | PairCorr |
| 0.46 | VERV | Verve Therapeutics | PairCorr |
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 9.89 | Revenue Per Share 0.749 | Quarterly Revenue Growth (0.10) | Return On Assets (0.33) | Return On Equity (1.38) |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.